INmune Bio (INMB) Q1 2025 Earnings
INMB·Reported May 8, 2025·After market close
INmune Bio reported Q1 2025 revenue of $50.0K (+257.1% YoY). Diluted EPS came in at $-0.43 (+29.5% YoY).
Revenue
$50.0K
Diluted EPS
$-0.43met estimate
Consensus: $-0.43
Financial Snapshot
Trailing eight quarters through Q1 2025
Q1 2025 Earnings FAQ
Common questions about INmune Bio's Q1 2025 earnings report.
INmune Bio (INMB) reported Q1 2025 earnings on May 8, 2025 after market close.
INmune Bio reported revenue of $50.0K and diluted EPS of $-0.43 for Q1 2025.
EPS beat the consensus estimate of $-0.43 by $0.00.
Compared to the same quarter a year prior, revenue grew 257.1% from $14.0K a year earlier and diluted EPS grew 29.5% from $-0.61.
You can read the 10-Q periodic report (0001213900-25-041072) directly on SEC EDGAR. The filing index links above go to sec.gov.